A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

European Journal of Haematology

Volumn 81, Issue 4, 2008, Pages 247-252

  Von Lilienfeld Toal, Marie ^a,b,c   Hahn Ast, Corinna ^b   Furkert, Kerstin ^b   Hoffmann, Florian ^b   Naumann, Ralph ^d   Bargou, Ralf ^e   Cook, Gordon ^c   Glasmacher, Axel ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Dexamethasone; Multiple myeloma; Relapsed refractory; Systematic review; Thalidomide

Indexed keywords

DEXAMETHASONE; THALIDOMIDE;

CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPSIS; SKIN INFECTION; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; URINARY TRACT INFECTION; VEIN THROMBOSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CONSTIPATION; DEXAMETHASONE; DISORDERS OF EXCESSIVE SOMNOLENCE; HUMANS; META-ANALYSIS AS TOPIC; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; RECURRENCE; THALIDOMIDE; VENOUS THROMBOEMBOLISM;

EID: 51649117633     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01121.x     Document Type: Review

References (19)

1. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, Orlopp K, Schmidt-Wolf I, Gorschluter M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006 132 : 584 93.
2. Prince HM, Schenkel B, Mileshkin L. An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007 48 : 46 55.
3. Anagnostopoulos A, Weber D, Rankin K, Delasalle K, Alexanian R. Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003 121 : 768 71.
4. Dimopoulos MA, Zervas K, Kouvatseas G, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001 12 : 991 5.
5. Palumbo A, Bertola A, Falco P, et al. Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J 2004 5 : 318 24.
6. Fermand J, Jaccard A, Macro M, Uzunhan Y, Allard C, Castaigne S, Divine M, Mariette X, Leblond V, Chevret S. A Randomized comparison of dexamethasone + thalidomide (Dex/Thal) vs dex + placebo (Dex/P) in patients (pts) with relapsing multiple myeloma (MM). Blood 2006 108 : 1017A 8A. [abstract no. 3563].
7. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006 296 : 2558 60.
8. Caravita T, Siniscalchi A, Santinelli S, Postorino M, Franchi A, Masi M, Amadori S. Low dose thalidomide plus dexamethasone for relapsed/refractory multiple myeloma: a single center experience. The Hematol J 2003 4 : S237. [abstract no. 333].
9. Kinoshita T, Ohno T, Yuge M, Hiraga J, Matsushita T, Ando S, Naoe T. Phase II study of thalidomide with dexamethasone for relapsed/refractory multiple myeloma. Ann Oncol 2005 16 : V 206. [abstract no. 579].
10. Linder O, Tidefelt U. Thalidomide combined with dexamethasone and pamidronate to patients with advanced myeloma, better than thalidomide alone? Blood 2000 96 : 290 B. [abstract no. 4996].
11. Musto P, Falcone A, Sanpaolo G, et al. A combined therapy with thalidomide, dexamethasone and zolendronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. Blood 2002 100 : 388 B. [abstract no. 5116].
12. Ochiai N, Yamada N, Uchida R, Fuchida S, Okano A, Hatsuse M, Okamoto M, Ashihara E, Shimazaki C. Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. Int J Hematol 2005 82 : 243 7.
13. Schütt P, Ebeling P, Buttkereit U, et al. Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival. Ann Hematol 2005 84 : 594 600.
14. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, Dimopoulos MA, Zervas K. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005 19 : 1969 76.
15. Tosi P, Zamagni E, Cellini C, Cangini D, Tura S, Baccarani M, Cavo M. Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced relapsed and refractory multiple myeloma. Blood 2001 98 : 163 A. [abstract no. 687].
16. Murakami H, Handa H, Abe M, et al. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma. Eur J Haematol 2007 26 : 234 9.
17. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008 22 : 414 23.
18. Neben K, Moehler T, Benner A, Kraemer A, Egerer G, Ho AD, Goldschmidt H. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002 8 : 3377 82.
19. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, Abonour R, Siegel D, Greipp P. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2007 25 LBA 8025. [abstract no. LBA8025].